Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome.

ABSTRACT:

Background and aims

Irritable bowel syndrome (IBS) is linked to post-inflammatory and stress-correlated factors that cause changes in the perception of visceral events. Probiotic bacteria may be effective in treating IBS symptoms. Here, we have investigated whether early life administration of VSL#3, a mixture of 8 probiotic bacteria strains, protects against development of visceral hypersensitivity driven by neonatal maternal separation (NMS), a rat model of IBS.

Methods

Male NMS pups were treated orally with placebo or VSL#3 from days 3 to 60, while normal, not separated rats were used as controls. After 60 days from birth, perception of painful sensation induced by colorectal distension (CRD) was measured by assessing the abdominal withdrawal reflex (score 0-4). The colon

SUBMITTER: Distrutti E 

PROVIDER: S-EPMC3655059 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature